TLC-3595 is under clinical development by OrsoBio and currently in Phase II for Insulin Resistance. According to GlobalData, Phase II drugs for Insulin Resistance does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the TLC-3595 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TLC-3595 is under development for the treatment of insulin resistance and type 2 diabetes. The drug candidate is administered by oral route. It acts by targeting acetyl-CoA-carboxylase 2. It was under development for the treatment of diabetes and non-alcoholic steatohepatitis (NASH).
OrsoBio formerly Liver, is a clinical-stage biopharmaceutical company that engaged in developing therapies for the treatment of severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. The company is headquartered in Palo Alto, California, the US.
For a complete picture of TLC-3595’s drug-specific PTSR and LoA scores, buy the report here.